These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 37379072)

  • 1. The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
    Oliver KE; Carlon MS; Pedemonte N; Lopes-Pacheco M
    Expert Opin Pharmacother; 2023; 24(14):1545-1565. PubMed ID: 37379072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule drugs for cystic fibrosis: Where are we now?
    Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
    Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
    Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting ion channels in cystic fibrosis.
    Mall MA; Galietta LJ
    J Cyst Fibros; 2015 Sep; 14(5):561-70. PubMed ID: 26115565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
    Larsen MB; Choi JJ; Wang X; Myerburg MM; Frizzell RA; Bertrand CA
    Am J Physiol Lung Cell Mol Physiol; 2021 Dec; 321(6):L1147-L1160. PubMed ID: 34668421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of CFTR modulators for the treatment of cystic fibrosis.
    Lopes-Pacheco M; Pedemonte N; Veit G
    Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ion Channel Modulators in Cystic Fibrosis.
    Gentzsch M; Mall MA
    Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
    Sato Y; Thomas DY; Hanrahan JW
    J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New horizons in the treatment of cystic fibrosis.
    Cuthbert AW
    Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis.
    Pinto MC; Silva IAL; Figueira MF; Amaral MD; Lopes-Pacheco M
    J Exp Pharmacol; 2021; 13():693-723. PubMed ID: 34326672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
    Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
    Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
    [No Abstract]   [Full Text] [Related]  

  • 15. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
    Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
    Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of single nucleotide variants in SLC26A9 gene in patients with cystic fibrosis (p.Phe508del homozygous) and its association to Orkambi® (Lumacaftor and Ivacaftor) response in vitro.
    Santos LG; Pereira SV; Kmit AHP; Bonadia LC; Bertuzzo CS; Ribeiro JD; Mazzola TN; Marson FAL
    Gene; 2023 Jun; 871():147428. PubMed ID: 37068695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.
    Eastman AC; Pace RG; Dang H; Aksit MA; Vecchio-Pagán B; Lam AN; O'Neal WK; Blackman SM; Knowles MR; Cutting GR
    J Cyst Fibros; 2021 Sep; 20(5):851-856. PubMed ID: 33674211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.